Zai Lab Limited ADR
ZLABHealthcare·Biotechnology·China·Mid·NASD·Nov 12 • 3:59 PM ET
26.04-0.38 (-1.44%)
2026-11-13 12:58 CET
Market cap
$2.94B
Revenue, TTM
443.04 USD m
Net income, TTM
-198.97 USD m
Free cash flow, TTM
-160.07 USD m
EPS diluted, TTM
-1.79
Price
ZLAB against its 20, 50 and 200-day averagesPatternshover a marker to name it
10.3% under the 52-week high of 29.02 on 9 Nov 2026. 52-week low 15.96 on 2 Feb 2026. Last 15 sessions, 35.5% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 19
CANSLIM 1 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 5 of 6 — fails: 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 3 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: Float: Under 100M; Performance: Year +50%
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Performance: Year +100%
Profile
ZLAB52-week range, 77% of the way up
15.9629.02
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
| Employees | 1784 |
|---|---|
| IPO | Sep 20, 2017 |
| Beta | 0.71 |
| ATR, 14d | 1.44 |
| Rel volume | 0.00 |
| Short float | 7.72% |
| Insider own | 7.07% |
| Inst own | 33.64% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $2.94B |
| Enterprise Value | 2.55B |
| Income | -198.97M |
| Sales | 443.04M |
| Book / share | 5.01 |
| Cash / share | 5.85 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 1784 |
| IPO | Sep 20, 2017 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 6.63 |
| Price / book | 5.20 |
| Price / cash | 4.45 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 5.75 |
| Quick Ratio | 1.84 |
| Current Ratio | 2.04 |
| Debt / equity | 0.47 |
| Long-term debt / equity | 0.02 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.79 |
|---|---|
| Earnings next year | -2.05 |
| Earnings next quarter | -0.54 |
| Earnings this year | -32.71% |
| Earnings next year | 3.51% |
| Earnings growth, 5 years | 8.20% |
| Past earnings growth | 29.68% 14.26% |
| Past sales growth | 29.03% 56.57% |
| Earnings vs last year | 8.33% |
| Sales vs last year | 0.25% |
| Earnings vs last quarter | -26.05% |
| Sales vs last quarter | -6.67% |
| Earnings | Nov 05 BMO |
| Surprise | 30.72% 0.29% |
Ownership
| Insiders own | 7.07% |
|---|---|
| Insider trades | -3.11% |
| Institutions own | 33.64% |
| Institution trades | -0.07% |
| Return on assets | -18.23% |
| Return on equity | -30.07% |
| Return on capital | -34.73% |
| Gross Margin | 54.69% |
| Operating margin | -62.99% |
| Profit Margin | -44.91% |
| 20-day average | 8.90% |
| 50-day average | 5.58% |
| 200-day average | 22.48% |
Technical
| Shares out | 112.43M |
|---|---|
| Shares floating | 104.83M |
| Short / float | 7.72% |
| Short ratio | 7.84 |
| Short interest | 8.09M |
| 52-week high | 29.02 -10.3% |
| 52-week low | 15.96 +63.2% |
| Volatility | 6.59% 5.39% |
| Average range | 1.44 |
| Strength index | 58.58 |
| Market sensitivity | 0.71 |
| Relative volume | 0.00 |
| Avg Volume | 1.03M |
| Volume | 0 |
Performance
| Perf Week | 15.22% |
|---|---|
| Perf Month | 15.73% |
| Perf Quarter | 0.54% |
| Perf Half Y | 28.09% |
| Perf YTD | 47.62% |
| Perf Year | 19.01% |
| Perf 3Y | -7.56% |
| Perf 5Y | -69.43% |
| Perf 10Y | - |
| Recommendation | 1.38 |
| Target Price | 34.41 |
| Prev Close | 26.04 |
| Price | 26.04 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 17| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Aug 25, 2025 | Resumed | Jefferies | Buy | $52 | +99.7% |
| Mar 07, 2025 | Initiated | Scotiabank | Sector Outperform | $55 | +111.2% |
| Mar 03, 2025 | Downgrade | BofA Securities | Buy → Neutral | $29 → $36.10 | +38.6% |
| Dec 14, 2023 | Initiated | Morgan Stanley | Overweight | $47.50 | +82.4% |
| Aug 10, 2023 | Initiated | Cantor Fitzgerald | Overweight | $70 | +168.8% |
| Jan 21, 2022 | Initiated | Macquarie | Outperform | $64 | +145.8% |
| Oct 12, 2021 | Initiated | Bernstein | Mkt Perform | ||
| Apr 28, 2020 | Initiated | Goldman | Buy | ||
| Apr 15, 2020 | Initiated | Guggenheim | Buy | $75 | +188.0% |
| Jul 12, 2019 | Initiated | BofA/Merrill | Buy |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ONC | BeOne Medicines Ltd ADR | 43.79B |
| HCM | HUTCHMED (China) Limited ADR | 2.59B |
| AAPG | Ascentage Pharma Group International ADR | 1.38B |
| LEGN | Legend Biotech Corp ADR | 3.60B |
| ARGX | Argen X SE ADR | 61.91B |
| ANL | Adlai Nortye Group Ltd ADR | 617.84M |
| NVCR | NovoCure Ltd | 1.37B |
| ADAG | Adagene Inc ADR | 134.28M |
| BMY | Bristol-Myers Squibb Co | 127.39B |
| GSK | GSK Plc ADR | 101.25B |
Insider trading
latest 14 of 87| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Chen Yajing | Chief Financial Officer | Aug 19 '26 | Sale | 27.00 | 260 | 7,020 | 35,635 | Aug 21 04:16 PM |
| Smiley Joshua L | Former Officer | Aug 20 '26 | Proposed Sale | 26.18 | 98,653 | 2,582,511 | Aug 20 04:20 PM | |
| Chen Yajing | Officer | Aug 19 '26 | Proposed Sale | 27.00 | 260 | 7,020 | Aug 19 01:51 PM | |
| Lis William | Director | Aug 12 '26 | Sale | 25.00 | 8,506 | 212,650 | 41,931 | Aug 13 04:15 PM |
| Chen Yajing | Chief Financial Officer | Aug 11 '26 | Sale | 25.00 | 619 | 15,475 | 35,072 | Aug 13 04:15 PM |
| Lis William | Director | Aug 12 '26 | Proposed Sale | 25.00 | 8,506 | 212,650 | Aug 12 10:42 AM | |
| Chen Yajing | Officer | Aug 11 '26 | Proposed Sale | 25.00 | 619 | 15,475 | Aug 11 04:22 PM | |
| GAYNOR RICHARD | Director | Jul 01 '26 | Buy | 19.05 | 1,736 | 33,071 | 80,737 | Jul 06 04:14 PM |
| Du Ying | Chairperson & CEO | Jun 30 '26 | Sale | 18.53 | 7,026 | 130,220 | 1,203,784 | Jul 01 04:24 PM |
| Du Ying | Officer | Jun 30 '26 | Proposed Sale | 18.53 | 7,026 | 130,220 | Jun 30 03:13 PM | |
| Edmondson Frazor Titus III | Chief Legal Officer | Jun 26 '26 | Sale | 17.46 | 4,103 | 71,642 | 30,346 | Jun 29 04:18 PM |
| Du Ying | Chairperson & CEO | Jun 26 '26 | Sale | 17.46 | 24,543 | 428,545 | 1,192,840 | Jun 29 04:17 PM |
| Chen Yajing | Chief Financial Officer | Jun 26 '26 | Sale | 17.46 | 2,264 | 39,532 | 35,691 | Jun 29 04:17 PM |
| Chen Yajing | Officer | Jun 26 '26 | Proposed Sale | 17.46 | 2,264 | 39,532 | Jun 26 03:38 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| CANC | Tema Oncology ETF | AUM: 215.24M |
| SBIO | ALPS Medical Breakthroughs ETF | AUM: 195.04M |
| BBP | Virtus Biotech ETF | AUM: 136.32M |
| PGJ | Invesco Golden Dragon China ETF | AUM: 78.50M |
| ONEQ | Fidelity Nasdaq Composite Index ETF | AUM: 10.51B |
| FMED | Fidelity Disruptive Medicine ETF | AUM: 30.30M |
| SPGM | State Street SPDR Portfolio MSCI Global Stock Market ETF | AUM: 1.81B |
| IBBQ | Invesco Nasdaq Biotechnology ETF | AUM: 130.85M |
| NSI | National Security Emerging Markets Index ETF | AUM: 41.03M |
News
latest 14 of 200- Zai Lab's Zoci Data Outshine A Stalling China Business As Losses Widen And Revenue Growth Slows (Earnings Whispers)
- Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas (Business Wire)
- Zai Lab's Rally Meets A Test: Can Sequential Sales Gains Hold As Cash Burn Persists? (Earnings Whispers)
- Zai Lab Announces $250 Million Private Placement (Business Wire) -8.93% +9.03%
- Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 (Business Wire)
- Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31R Bispecific Antibody, for Atopic Diseases (Business Wire)
- Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (Business Wire)
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis (Business Wire)
- Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ... (GuruFocus.com) +13.66%
- Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
- U.S. FDA Grants Orphan Drug Designation to Zai Labs DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) (Business Wire)
- Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 (Business Wire)
- Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas (Business Wire)
- Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
Quarterly earnings
2026Q3 EPS -0.410 beat -0.592, from -0.330 a year earlier. Sales 108.21 beat 107.9, from 116.1 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-05 08:30 | -0.410 | -0.592 | -0.411 | 108.21 | 107.9 | EPS -30.7% · sales +0.3% | vs 2025Q3, year-ago quarter · EPS +24.2% · sales -6.8% | 6 | Open +0.48% vs SPY -0.17%. Close -0.88% vs SPY -4.41% |
| 2026Q2ended 2026-06-30 | 2026-08-06 08:30 | -0.500 | -0.679 | -0.456 | 106.31 | 103.87 | EPS -26.4% · sales +2.4% | vs 2025Q2, year-ago quarter · EPS +35.1% · sales -3.3% | 6 | Open +3.70% vs SPY +0.05%. Close +13.66% vs SPY -0.16% |
| 2026Q1ended 2026-03-31 | 2026-05-07 08:30 | -0.460 | -0.526 | -0.462 | 99.61 | 108.43 | EPS -12.6% · sales -8.1% | vs 2025Q1, year-ago quarter · EPS +1050.0% · sales -6.5% | 5 | Open -2.28% vs SPY +0.17%. Close -5.93% vs SPY -0.31% |
| 2025Q4ended 2025-12-31 | 2026-02-26 08:30 | -0.460 | -0.359 | -0.458 | 127.6 | 122.16 | EPS +28.1% · sales +4.4% | vs 2024Q4, year-ago quarter · EPS -42.5% · sales +17.0% | 5 EPS · 7 sales | Open -3.04% vs SPY +0.02%. Close +1.55% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-06 08:30 | -0.330 | -0.289 | -0.327 | 116.1 | 141.71 | EPS +14.2% · sales -18.1% | vs 2024Q3, year-ago quarter · EPS +725.0% · sales +13.5% | 7 | Open -6.61% vs SPY -0.16%. Close -6.65% vs SPY -1.07% |
| 2025Q2ended 2025-06-30 | 2025-08-07 08:30 | -0.370 | -0.358 | -0.374 | 109.98 | 124.95 | EPS +3.3% · sales -12.0% | vs 2024Q2, year-ago quarter · EPS -54.9% · sales +9.9% | 7 | Open -10.95% vs SPY +0.55%. Close -11.98% vs SPY -0.08% |
| 2025Q1ended 2025-03-31 | 2025-05-08 08:30 | -0.040 | -0.554 | -0.449 | 106.49 | 112.58 | EPS -92.8% · sales -5.4% | vs 2024Q1, year-ago quarter · EPS -92.7% · sales +22.2% | 6 EPS · 7 sales | Open +0.18% vs SPY +0.73%. Close +2.75% vs SPY +0.70% |
| 2024Q4ended 2024-12-31 | 2025-02-27 08:30 | -0.800 | -0.651 | -0.800 | 109.07 | 109.34 | EPS +22.9% · sales -0.2% | vs 2023Q4, year-ago quarter · EPS -50.9% · sales +65.7% | 6 EPS · 7 sales | Open -1.43% vs SPY +0.39%. Close -1.97% vs SPY -1.60% |
| 2024Q3ended 2024-09-30 | 2024-11-12 08:30 | -0.040 | -0.783 | -0.428 | 102.27 | 102.24 | EPS -94.9% · sales +0.0% | vs 2023Q3, year-ago quarter · EPS -42.9% · sales +47.7% | 6 | Open -1.77% vs SPY -0.01%. Close -6.85% vs SPY -0.31% |
| 2024Q2ended 2024-06-30 | 2024-08-06 16:30 | -0.820 | -0.708 | -0.822 | 100.11 | 93.16 | EPS +15.8% · sales +7.5% | vs 2023Q2, year-ago quarter · EPS -34.4% · sales +45.4% | 6 | Open +13.20% vs SPY +1.21%. Close -8.06% vs SPY -0.67% |
| 2024Q1ended 2024-03-31 | 2024-05-08 16:30 | -0.550 | -0.925 | -0.549 | 87.15 | 75.24 | EPS -40.5% · sales +15.8% | vs 2023Q1, year-ago quarter · EPS +7.8% · sales +38.8% | 6 | Open +21.00% vs SPY +0.04%. Close +26.80% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-02-27 16:30 | -1.630 | -0.856 | -0.991 | 65.82 | 72.14 | EPS +90.5% · sales -8.8% | vs 2022Q4, year-ago quarter · EPS +150.8% · sales +5.1% | 6 | Open -3.07% vs SPY -0.32%. Close -7.51% vs SPY -0.13% |
| 2023Q3ended 2023-09-30 | 2023-11-07 16:30 | -0.070 | -1.044 | -0.714 | 69.23 | 66.41 | EPS -93.3% · sales +4.2% | vs 2022Q3, year-ago quarter · EPS -95.8% · sales +20.3% | 6 EPS · 5 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-07 16:30 | -1.250 | -0.790 | -1.239 | 68.86 | 70.48 | EPS +58.1% · sales -2.3% | vs 2022Q2, year-ago quarter · EPS -13.2% · sales +42.9% | 5 | - |
| 2023Q1ended 2023-03-31 | 2023-05-09 16:30 | -0.510 | -0.948 | -0.510 | 62.80 | 65.12 | EPS -46.2% · sales -3.6% | vs 2022Q1, year-ago quarter · EPS -40.7% · sales +34.4% | 5 | - |
| 2022Q4ended 2022-12-31 | 2023-03-01 16:30 | -0.650 | -1.109 | -0.642 | 62.60 | 62.79 | EPS -41.4% · sales -0.3% | vs 2021Q4, year-ago quarter · EPS -70.0% · sales +41.7% | 5 EPS · 3 sales | - |
Annual earnings
2025FY EPS -1.600 beat -1.756, from -2.600 a year earlier. Sales 460.16 missed 461.1, from 398.99 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 1.753 | - | - | 1,312 | 14.85 |
| 2029FYestimate | - | 0.690 | - | - | 1,048 | 37.75 |
| 2028FYestimate | - | -1.238 | - | - | 704.86 | - |
| 2027FYestimate | - | -2.049 | - | - | 503.33 | - |
| 2026FYestimate | - | -2.123 | - | - | 422.95 | - |
| 2025FY | -1.600 | -1.756 | -1.633 | 460.16 | 461.1 | - |
| 2024FY | -2.600 | -2.683 | -2.600 | 398.99 | 393.4 | - |
| 2023FY | -3.460 | -3.581 | -3.460 | 266.72 | 267.09 | - |
| 2022FY | -4.630 | -4.903 | -4.621 | 215.04 | 214.43 | - |
| 2021FY | -7.580 | -6.014 | -7.586 | 144.31 | 151.28 | - |
| 2020FY | -3.460 | -3.082 | -3.468 | 48.96 | 57.43 | - |
| 2019FY | -2.975 | -2.657 | -2.225 | 12.99 | 8.42 | - |
| 2018FY | -2.635 | -1.493 | -1.582 | 0.06 | 0.20 | - |
| 2017FY | -2.320 | -1.096 | -0.576 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 108.5, from 116.25 a year earlier. Operating margin -58.2%, from -42.1% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.12 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-08 | -2.12 | 0.0% |
| 2026Q4 | E | per share | 2026-11-08 | -0.54 | 0.0% |
| 2026FY | R | per share | 2026-11-08 | -2.15 | 0.0% |
| 2026Q4 | R | per share | 2026-11-08 | -0.53 | 0.0% |
| 2026Q4 | S | - | 2026-11-08 | 104.48 | 0.0% |
| 2026FY | S | - | 2026-11-05 | 422.95 | +0.6% |
| 2026Q3 | E | per share | 2026-11-02 | -0.59 | +4.9% |
| 2026Q3 | R | per share | 2026-11-02 | -0.58 | +16.7% |
| 2026Q3 | S | - | 2026-11-02 | 107.9 | -0.9% |
| 2026Q2 | E | per share | 2026-08-06 | -0.64 | -6.1% |
| 2026Q2 | S | - | 2026-08-06 | 103.48 | -0.4% |
| 2026Q2 | R | per share | 2026-07-24 | -0.79 | +4.7% |
| 2026Q1 | E | per share | 2026-05-01 | -0.53 | +4.4% |
| 2026Q1 | S | - | 2026-05-01 | 108.43 | -3.7% |
| 2026Q1 | R | per share | 2026-04-21 | -0.54 | +22.3% |
| 2025FY | R | per share | 2026-02-26 | -1.82 | +5.9% |
| 2025Q4 | R | per share | 2026-02-26 | -0.32 | +7.5% |
| 2025FY | E | per share | 2026-02-23 | -1.73 | 0.0% |
| 2025Q4 | E | per share | 2026-02-20 | -0.36 | +7.3% |
| 2025FY | S | - | 2026-02-20 | 460.29 | -0.1% |
| 2025Q4 | S | - | 2026-02-20 | 122.16 | -0.8% |
| 2025Q3 | E | per share | 2025-10-25 | -0.29 | 0.0% |
| 2025Q3 | R | per share | 2025-10-25 | -0.28 | 0.0% |
| 2025Q3 | S | - | 2025-10-25 | 141.71 | 0.0% |
| 2025Q2 | S | - | 2025-08-06 | 124.95 | 0.0% |
| 2025Q2 | E | per share | 2025-07-22 | -0.42 | 0.0% |
| 2025Q2 | R | per share | 2025-07-11 | -0.35 | -20.5% |
| 2025Q1 | E | per share | 2025-05-01 | -0.48 | +0.6% |
| 2025Q1 | S | - | 2025-05-01 | 112.58 | -0.4% |
| 2025Q1 | R | per share | 2025-03-12 | -0.25 | -47.0% |
| 2024FY | E | per share | 2025-02-27 | -2.70 | +0.5% |
| 2024Q4 | E | per share | 2025-02-27 | -0.63 | -2.7% |
| 2024FY | S | - | 2025-02-27 | 392.77 | -0.2% |
| 2024Q4 | S | - | 2025-02-27 | 109.14 | -0.2% |
| 2024FY | R | per share | 2025-02-03 | -2.83 | 0.0% |
| 2024Q4 | R | per share | 2025-02-03 | -0.60 | 0.0% |
| 2024Q3 | E | per share | 2024-10-24 | -0.78 | +1.1% |
| 2024Q3 | S | - | 2024-10-24 | 102.24 | -1.2% |
| 2024Q3 | R | per share | 2024-10-23 | -0.69 | -1.4% |
| 2024Q2 | E | per share | 2024-07-24 | -0.71 | 0.0% |
| 2024Q2 | S | per share | 2024-07-24 | 93.16 | 0.0% |
| 2024Q2 | R | per share | 2024-07-12 | -0.61 | -0.8% |
| 2024Q1 | E | per share | 2024-04-19 | -0.92 | -1.1% |
| 2024Q1 | S | per share | 2024-04-19 | 75.24 | +1.7% |
| 2024Q1 | R | per share | 2024-04-17 | -0.93 | +9.4% |
| 2023FY | E | per share | 2024-02-22 | -3.58 | -0.6% |
| 2023FY | S | - | 2024-02-22 | 267.09 | 0.0% |
| 2023FY | R | per share | 2024-02-21 | -3.72 | +0.3% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.576 | -1.582 | -2.225 | -3.468 | -7.586 | -4.621 | -3.46 | -2.6 | -1.607 | -1.7874 | - |
| Sales USD millions | 0 | 0 | 13 | 49 | 145 | 215 | 266 | 399 | 461 | 443 | - |
| Shares million shares | 88 | 88 | 88 | 88 | 96 | 96 | 97 | 108 | 111 | - | 112 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.428 | -0.8 | -0.449 | -0.374 | -0.327 | -0.458 | -0.462 | -0.456 | -0.412 |
| Sales USD millions | 103 | 109 | 107 | 110 | 116 | 128 | 100 | 106 | 108 |
| Shares million shares | 98 | 108 | 108 | 110 | 111 | 111 | 111 | 112 | 112 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 443.04 | 461.37+15.6% | 399.19+49.8% | 266.49+24.1% | 214.78+48.6% | 144.50+194.7% | 49.04+276.9% | 13.01+9907.7% | 0.13 |
| Cost of Goods Sold Incl. D&A | 200.74 | 191.59+29.5% | 147.93+54.5% | 95.73+29.5% | 73.93+41.3% | 52.31+212.1% | 16.76+63.2% | 10.27+507.7% | 1.69 |
| Gross Profit | 242.31 | 269.79+7.4% | 251.25+47.1% | 170.75+21.2% | 140.85+52.8% | 92.20+185.6% | 32.28+1082.4% | 2.73 | -1.56 |
| Selling, General and Administrative Excl. Other | 521.37 | 499.83-6.3% | 533.51-2.5% | 547.00+0.4% | 544.73-31.3% | 793.19+137.1% | 334.60+62.2% | 206.28+47.3% | 140.08 |
| Research and Development | 239.50 | 221.49-5.6% | 234.62-11.7% | 265.64-7.1% | 286.07-50.2% | 574.07+157.3% | 223.09+56.6% | 142.47+18.6% | 120.17 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -279.06 | -230.04 | -282.26 | -376.25 | -403.88 | -700.99 | -302.32 | -203.55 | -141.64 |
| Interest Expense | 6.18 | 5.22+131.0% | 2.26 | 0.00 | - | - | 0.18-37.9% | 0.29+625.0% | 0.04 |
| Unusual Expense | - | 1.92-68.6% | 6.11 | -2.79-131.2% | 8.94-38.9% | 14.64 | 0.00 | - | 0.00 |
| Net Income Before Taxes | -203.36 | -178.94 | -257.23 | -334.33 | -442.54 | -704.35 | -268.25 | -194.65 | -138.36 |
| Income Taxes | -4.40 | -2.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -198.97 | -176.00 | -257.23 | -334.33 | -442.76 | -705.41 | -269.37 | -195.41 | -138.95 |
| Net Income From Continuing Operations | -198.97 | -176.00 | -257.23 | -334.33 | -442.76 | -705.41 | -269.37 | -195.41 | -138.95 |
| Net Income | -198.97 | -176.00 | -257.23 | -334.33 | -442.76 | -705.41 | -269.37 | -195.41 | -138.95 |
| EPS (Recurring) per share | -1.77 | -1.59 | -2.56 | -3.48 | -4.56 | -7.48 | -3.47 | -2.23 | -1.58 |
| EPS (Basic, Before Extraordinaries) per share | -1.79 | -1.61 | -2.60 | -3.46 | -4.62 | -7.59 | -3.47 | -2.23 | -1.58 |
| EPS (Diluted) per share | -1.79 | -1.61 | -2.60 | -3.46 | -4.62 | -7.59 | -3.47 | -2.23 | -1.58 |
| EBITDA | -256.11 | -206.13 | -261.97 | -358.52 | -387.32 | -688.37 | -293.36 | -197.03 | -139.99 |
| Non-Operating Income (Expense) | 81.88 | 58.24+74.4% | 33.39-14.7% | 39.13 | -29.72-363.5% | 11.28-67.1% | 34.25+272.7% | 9.19+176.8% | 3.32 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 39.82 | 49.33-6.9% | 53.01-11.2% | 59.67+29.9% | 45.92+50.2% | 30.58+64.0% | 18.65+22.4% | 15.24+24.7% | 12.22 |
| Price To Sales Ratio ratio | 6.68 | 4.19 | 6.49 | 9.91 | 13.69 | 40.45 | 214.34 | 280.77 | 15,764.94 |
| Gross Margin % | 54.69 | 58.47 | 62.94 | 64.08 | 65.58 | 63.80 | 65.82 | 21.01 | -1,208.10 |
| Operating Margin % | -62.99 | -49.86 | -70.71 | -141.19 | -188.04 | -485.10 | -616.45 | -1,564.85 | -109,513.87 |
| Net Margin % | -44.91 | -38.15 | -64.44 | -125.46 | -206.14 | -488.16 | -549.26 | -1,502.28 | -107,433.42 |
| Shares Outstanding million shares | 112.43 | 110.64+2.7% | 107.77+10.9% | 97.22+1.2% | 96.02+0.5% | 95.54+8.8% | 87.810.0% | 87.810.0% | 87.81 |
| Market Capitalization | 2,937.44 | 2,937.44+3.0% | 2,853.06+6.1% | 2,687.89-10.4% | 2,999.33-50.0% | 5,994.70-49.7% | 11,913.20+332.7% | 2,753.22+134.5% | 1,173.91 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 108.50-6.7% | 106.49-3.5% | 99.91-6.3% | 128.15+17.9% | 116.25+12.8% | 110.37+9.9% | 106.64+22.6% | 108.68+63.9% |
| Cost of Goods Sold Incl. D&A | 51.44+9.6% | 48.24+11.2% | 38.45-0.6% | 62.60+49.3% | 46.95+26.1% | 43.37+23.2% | 38.70+15.3% | 41.94+65.1% |
| Gross Profit | 57.05-17.7% | 58.25-13.0% | 61.46-9.5% | 65.55-1.8% | 69.30+5.2% | 66.99+2.8% | 67.94+27.1% | 66.74+63.3% |
| Selling, General and Administrative Excl. Other | 120.20+1.7% | 134.86+10.5% | 131.05+5.4% | 135.26+0.6% | 118.19-12.0% | 122.08-13.5% | 124.33+0.6% | 134.39-18.9% |
| Research and Development | 49.94+4.1% | 61.87+21.8% | 65.79+8.2% | 61.90+18.9% | 47.99-27.9% | 50.79-17.5% | 60.82+11.5% | 52.06-36.9% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -63.15 | -76.62 | -69.59 | -69.71 | -48.89 | -55.09 | -56.39 | -67.65 |
| Interest Expense | 1.58+12.9% | 1.59+25.2% | 1.64+37.8% | 1.37+52.2% | 1.40+86.7% | 1.27+159.2% | 1.19+981.8% | 0.90 |
| Unusual Expense | 0.00 | 0.00 | 0.00-100.0% | - | 0.00-100.0% | 0.00-100.0% | 1.91 | 0.04 |
| Net Income Before Taxes | -48.14 | -51.93 | -49.72 | -53.57 | -36.01 | -40.87 | -48.51 | -81.39 |
| Income Taxes | -1.88 | -1.02 | 1.44 | -2.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -46.26 | -50.91 | -51.17 | -50.63 | -36.01 | -40.87 | -48.51 | -81.39 |
| Net Income From Continuing Operations | -46.26 | -50.91 | -51.17 | -50.63 | -36.01 | -40.87 | -48.51 | -81.39 |
| Net Income | -46.26 | -50.91 | -51.17 | -50.63 | -36.01 | -40.87 | -48.51 | -81.39 |
| EPS (Recurring) per share | -0.41 | -0.46 | -0.46 | -0.46 | -0.33 | -0.37 | -0.44 | -0.80 |
| EPS (Basic, Before Extraordinaries) per share | -0.41 | -0.46 | -0.46 | -0.46 | -0.33 | -0.37 | -0.45 | -0.80 |
| EPS (Diluted) per share | -0.41 | -0.46 | -0.46 | -0.46 | -0.33 | -0.37 | -0.45 | -0.80 |
| EBITDA | -57.32 | -70.74 | -63.86 | -64.18 | -43.11 | -48.36 | -50.42 | -62.32 |
| Non-Operating Income (Expense) | 16.59+16.2% | 26.27+69.7% | 21.51+95.7% | 17.51 | 14.28-49.1% | 15.48+145.3% | 10.99-8.7% | -12.80-153.4% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 8.53-32.9% | 9.11-28.7% | 10.20-14.1% | 11.98-7.0% | 12.71+0.1% | 12.78-31.4% | 11.87-11.8% | 12.88-16.7% |
| Price To Sales Ratio ratio | 6.68 | 4.71 | 4.58 | 4.23 | 8.45 | 8.91 | 9.33 | 6.68 |
| Gross Margin % | 52.59 | 54.70 | 61.52 | 51.15 | 59.62 | 60.70 | 63.71 | 61.41 |
| Operating Margin % | -58.20 | -71.95 | -69.66 | -54.39 | -42.05 | -49.91 | -52.88 | -62.25 |
| Net Margin % | -42.64 | -47.81 | -51.22 | -39.51 | -30.98 | -37.03 | -45.49 | -74.89 |
| Shares Outstanding million shares | 112.43+1.7% | 112.24+2.1% | 111.02+2.4% | 110.64+2.7% | 110.59+12.3% | 109.91+12.0% | 108.42+11.4% | 107.77+10.9% |
| Market Capitalization | 2,937.44-22.1% | 2,145.54-44.5% | 2,119.32-46.3% | 1,961.92-31.2% | 3,770.97+57.6% | 3,867.23+125.5% | 3,944.21+149.4% | 2,853.06+6.1% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 789.58-10.2% | 879.66+9.1% | 806.45-20.0% | 1,008.47-28.4% | 1,409.07+18.7% | 1,186.79+330.1% | 275.93+4.8% | 263.30+14.6% | 229.66 |
| Short Term Receivables | 118.29+32.3% | 89.41+36.9% | 65.33+34.5% | 48.57-11.4% | 54.81+960.2% | 5.17+36.4% | 3.79+4111.1% | 0.09 | 0.00 |
| Inventories | 74.75+87.5% | 39.87-11.1% | 44.83+41.8% | 31.62+66.9% | 18.95+44.2% | 13.14+119.0% | 6.00 | 0.00 | 0.00 |
| Other Current Assets | 36.68-11.7% | 41.53+80.6% | 23.00-35.5% | 35.67+97.9% | 18.02+64.7% | 10.94+62.3% | 6.74+17.2% | 5.75+505.3% | 0.95 |
| Total Current Assets | 1,019.29-3.0% | 1,050.48+11.8% | 939.61-16.4% | 1,124.34-25.1% | 1,500.85+23.4% | 1,216.04+315.8% | 292.46+8.7% | 269.14+16.7% | 230.61 |
| Net Property, Plant & Equipment | 66.54-4.2% | 69.47+1.1% | 68.69-12.8% | 78.77+35.2% | 58.28+23.6% | 47.14+27.9% | 36.86+77.5% | 20.77+73.4% | 11.98 |
| Total Investments and Advances | 1.12-73.5% | 4.23-59.1% | 10.33+42.9% | 7.23-55.9% | 16.41+712.4% | 2.02-30.6% | 2.91-7.6% | 3.15+60.7% | 1.96 |
| Long-Term Note Receivable | - | - | - | - | - | - | - | - | 0.00 |
| Intangible Assets | 76.14+35.9% | 56.03+318.4% | 13.39+786.8% | 1.51-18.4% | 1.85+20.9% | 1.53+33.0% | 1.15+259.4% | 0.32+1500.0% | 0.02 |
| Deferred Tax Assets | 3.39 | - | - | - | - | - | - | - | - |
| Other Assets | 5.91+6.7% | 5.54+29.4% | 4.28-48.4% | 8.29-74.5% | 32.54+5.3% | 30.91+42.0% | 21.77+153.1% | 8.60+70.0% | 5.06 |
| Total Assets | 1,172.39-1.1% | 1,185.75+14.4% | 1,036.30-15.1% | 1,220.14-24.2% | 1,609.92+24.1% | 1,297.64+265.4% | 355.15+17.6% | 301.98+21.0% | 249.63 |
| Short Term Debt Incl. Current Port. of LT Debt | 210.87+50.9% | 139.76+1868.5% | 7.10+0.7% | 7.05+18.9% | 5.93+13.8% | 5.21-51.8% | 10.80+196.7% | 3.64 | 0.00 |
| Accounts Payable | 141.61+40.3% | 100.91-10.7% | 112.99+71.3% | 65.97-47.7% | 126.16+101.4% | 62.64+176.4% | 22.66-39.5% | 37.43+317.3% | 8.97 |
| Income Tax Payable | 5.30+2.9% | 5.15-69.7% | 16.99+27.9% | 13.28+50.6% | 8.82 | - | - | - | - |
| Other Current Liabilities | 58.38+9.0% | 53.57-18.8% | 65.98+23.2% | 53.54+3.0% | 51.99+72.2% | 30.20+129.3% | 13.17+69.5% | 7.77+150.6% | 3.10 |
| Total Current Liabilities | 416.17+39.0% | 299.38+47.4% | 203.07+45.2% | 139.84-27.5% | 192.90+96.8% | 98.04+110.3% | 46.63-4.5% | 48.84+304.6% | 12.07 |
| Long Term Debt | 13.39-2.3% | 13.71+70.3% | 8.05-39.7% | 13.34+38.8% | 9.61-28.2% | 13.39+21.9% | 10.98 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 27.33-13.9% | 31.76+9.3% | 29.06+36.0% | 21.36-15.0% | 25.12+75.2% | 14.34+1567.4% | 0.86-58.3% | 2.06+39.2% | 1.48 |
| Total Liabilities | 456.89+32.5% | 344.85+43.6% | 240.18+37.6% | 174.55-23.3% | 227.63+81.0% | 125.77+115.1% | 58.47+14.9% | 50.90+275.6% | 13.55 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 2.37-6.0% | 2.52+24.8% | 2.02 | 0.00-100.0% | 0.91 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 715.50-14.9% | 840.90+5.6% | 796.12-23.9% | 1,045.60-24.2% | 1,379.93+18.0% | 1,169.35+296.8% | 294.66+17.4% | 251.08+6.8% | 235.17 |
| Total Shareholders Equity | 715.50-14.9% | 840.90+5.6% | 796.12-23.9% | 1,045.60-24.2% | 1,379.93+18.0% | 1,169.35+296.8% | 294.66+17.4% | 251.08+6.8% | 235.17 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 715.50-14.9% | 840.90+5.6% | 796.12-23.9% | 1,045.60-24.2% | 1,379.93+18.0% | 1,169.35+296.8% | 294.66+17.4% | 251.08+6.8% | 235.17 |
| Total Liabilities & Stockholders Equity | 1,172.39-1.1% | 1,185.75+14.4% | 1,036.30-15.1% | 1,220.14-24.2% | 1,609.92+24.1% | 1,297.64+265.4% | 355.15+17.6% | 301.98+21.0% | 249.63 |
| Book Value Per Share per share | 6.47-17.1% | 7.80-4.8% | 8.19-24.8% | 10.89-24.6% | 14.44+8.4% | 13.32+296.4% | 3.36+17.5% | 2.86+6.7% | 2.68 |
| Tangible Book Value Per Share per share | 5.78-20.6% | 7.28-9.6% | 8.05-25.9% | 10.87-24.6% | 14.42+8.4% | 13.30+298.2% | 3.34+16.8% | 2.86+6.7% | 2.68 |
| Full-Time Employees people | 1,784-4.5% | 1,869-14.1% | 2,175+6.8% | 2,036+4.4% | 1,951+63.4% | 1,194+72.5% | 692+123.9% | 309+251.1% | 88 |
| Price to Book Ratio ratio | 5.20 | 3.86 | 3.01 | 2.66 | 4.35 | 255.32 | 12.39 | 81.21 | -26.20 |
| Return on Assets % | -14.93 | -23.15 | -29.63 | -31.29 | -48.52 | -32.60 | -59.47 | -50.38 | -29.87 |
| Return on Equity % | -22.62 | -31.43 | -36.31 | -36.51 | -55.34 | -36.80 | -71.61 | -57.15 | -31.78 |
| Return on Invested Capital % | -24.15 | -30.10 | -41.57 | -41.81 | -50.77 | -22.77 | -63.93 | -55.34 | -21.50 |
| Quick Ratio ratio | 2.27 | 3.38 | 4.41 | 7.81 | 7.68 | 12.27 | 6.14 | 5.51 | 19.11 |
| Current Ratio ratio | 2.45 | 3.51 | 4.63 | 8.04 | 7.78 | 12.40 | 6.27 | 5.51 | 19.11 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -198.92 | -176.00 | -257.23 | -334.33 | -442.76 | -705.41 | -269.37 | -195.41 | -138.95 |
| Depreciation | 22.98 | 23.91+17.8% | 20.29+14.5% | 17.72+7.0% | 16.56+31.2% | 12.62+40.7% | 8.97+35.7% | 6.61+300.6% | 1.65 |
| Other Funds (Non Cash) | 25.71 | 55.76-37.8% | 89.69+13.5% | 79.03-36.9% | 125.17+4.6% | 119.68+365.9% | 25.69+23.6% | 20.78+66.4% | 12.49 |
| Funds from Operations | -156.51 | -99.68 | -147.25 | -237.58 | -301.04 | -573.10 | -234.70 | -168.02 | -124.81 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.59 | -51.51 | -68.42-272.9% | 39.57 | -66.17-386.0% | 23.14+26.6% | 18.28 | -23.32-185.2% | 27.36 |
| Cash from Operating Activities | -155.92 | -151.19 | -215.68 | -198.01 | -367.21 | -549.96 | -216.43 | -191.34 | -97.45 |
| Capital Expenditures | -38.04 | -13.46 | -61.55 | -8.48 | -24.95 | -18.97 | -10.69 | -15.27 | -10.11 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.27 | 0.09+200.0% | 0.03-75.0% | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -9.80 | 322.05 | -313.86 | -16.29-103.7% | 444.47+65.1% | 269.26 | -545.10-155842.9% | 0.35 | -202.25 |
| Purchase of Investments | -10.03 | -10.03 | -330.17 | -133.88 | -259.96 | -475.63 | -950.79 | -278.12 | -202.25 |
| Sale Or Maturity of Investments | 0.22 | 332.08+1936.1% | 16.31-86.1% | 117.60-83.3% | 704.44-5.4% | 744.89+83.6% | 405.70+45.7% | 278.47 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00-100.0% | 13.88 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Investing Activities | -47.58 | 308.68 | -375.38 | -10.77-102.6% | 419.52+67.6% | 250.29 | -555.79 | -14.92 | -212.36 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 4.80 | 12.85-94.1% | 219.38+9156.5% | 2.37-59.6% | 5.86-99.3% | 825.55-27.6% | 1,140.93+426.3% | 216.77+54.4% | 140.38 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 4.80 | 12.85-94.1% | 219.38+9156.5% | 2.37-59.6% | 5.86-99.3% | 825.55-27.6% | 1,140.93+426.3% | 216.77+54.4% | 140.38 |
| Proceedsfrom Stock Options | -0.00 | -0.86-100.4% | 216.18 | 0.00 | 0.00-100.0% | 818.12-27.9% | 1,134.25+425.8% | 215.72+53.7% | 140.38 |
| Issuance or Reduction of Debt, Net | 37.95 | 68.12-48.2% | 131.39 | 0.00 | 0.00 | 0.00 | -6.54-324.7% | 2.91-20.1% | 3.64 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -8.24 | -8.24 | 0.00 | -8.79 | -7.59 | -4.26 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -8.24 | -8.24 | 0.00 | -8.79 | -7.59 | -4.26 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 34.31 | 72.54-79.3% | 350.76 | -6.43 | -1.73-100.2% | 821.29-27.6% | 1,134.39+416.4% | 219.68+52.5% | 144.02 |
| Exchange Rate Effect | 1.50 | 0.48 | -0.31 | -2.62 | -6.27-659.8% | 1.12-77.0% | 4.87+5311.1% | 0.09 | -0.76 |
| Net Change in Cash | -167.69 | 230.52 | -240.60 | -217.82-591.5% | 44.32-91.5% | 522.74+42.4% | 367.05+2616.9% | 13.51 | -166.56 |
| Free Cash Flow | -160.07 | -159.31 | -221.34 | -205.21 | -391.76 | -568.28 | -226.57 | -197.39 | -107.46 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | -3.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 659.64-19.3% | 717.55-13.8% | 761.34-11.2% | 789.58-10.2% | 817.15+14.1% | 832.28+14.0% | 857.27+14.2% | 879.66+9.1% |
| Short Term Receivables | 75.40-28.2% | 72.99-26.5% | 62.00-29.3% | 118.29+32.3% | 105.00+51.6% | 99.34+27.8% | 87.67+15.7% | 89.41+36.9% |
| Inventories | 85.29+27.1% | 90.89+47.3% | 85.96+62.0% | 74.75+87.5% | 67.13+69.7% | 61.70+47.4% | 53.05+40.2% | 39.87-11.1% |
| Other Current Assets | 44.05+0.9% | 32.64-19.9% | 35.46-19.2% | 36.68-11.7% | 43.65+22.4% | 40.75+100.8% | 43.88+81.2% | 41.53+80.6% |
| Total Current Assets | 864.38-16.3% | 914.07-11.6% | 944.76-9.3% | 1,019.29-3.0% | 1,032.95+20.0% | 1,034.08+18.9% | 1,041.88+17.2% | 1,050.48+11.8% |
| Net Property, Plant & Equipment | 60.98-5.6% | 62.59-6.5% | 64.65-5.9% | 66.54-4.2% | 64.62+1.6% | 66.95+5.0% | 68.74+1.6% | 69.47+1.1% |
| Total Investments and Advances | 1.12+0.9% | 1.12+0.9% | 1.12+0.9% | 1.12-73.5% | 1.11-74.0% | 1.11-78.6% | 1.11-92.7% | 4.23-59.1% |
| Intangible Assets | 85.29+54.3% | 85.78+51.8% | 75.76+34.8% | 76.14+35.9% | 55.28+7.0% | 56.52+28.3% | 56.20+353.2% | 56.03+318.4% |
| Deferred Tax Assets | 6.48 | 4.85 | 3.44 | 3.39 | - | - | - | - |
| Other Assets | 5.62+12.9% | 6.43+17.8% | 6.04+11.4% | 5.91+6.7% | 4.98-4.8% | 5.46+23.3% | 5.42+20.2% | 5.54+29.4% |
| Total Assets | 1,023.87-11.7% | 1,074.83-7.7% | 1,095.77-6.6% | 1,172.39-1.1% | 1,158.94+17.6% | 1,164.12+17.9% | 1,173.34+18.7% | 1,185.75+14.4% |
| Short Term Debt Incl. Current Port. of LT Debt | 257.89+23.7% | 243.14+35.0% | 219.81+22.1% | 210.87+50.9% | 208.52+74.4% | 180.10+131.3% | 179.98+222.5% | 139.76+1868.5% |
| Accounts Payable | 120.24+20.6% | 136.70+27.3% | 126.17+22.5% | 141.61+40.3% | 99.71-17.4% | 107.36-15.7% | 103.02+16.9% | 100.91-10.7% |
| Income Tax Payable | 3.47-26.6% | 4.02-15.5% | 3.66-2.9% | 5.30+2.9% | 4.73+25.8% | 4.76+2.8% | 3.77-45.4% | 5.15-69.7% |
| Other Current Liabilities | 42.64-8.9% | 44.75+13.9% | 43.35+31.2% | 58.38+9.0% | 46.81+10.6% | 39.29-6.2% | 33.04-19.9% | 53.57-18.8% |
| Total Current Liabilities | 424.24+17.9% | 428.60+29.3% | 392.99+22.9% | 416.17+39.0% | 359.77+25.7% | 331.51+31.7% | 319.81+66.5% | 299.38+47.4% |
| Long Term Debt | 9.56-11.8% | 11.45+1.2% | 12.11-1.7% | 13.39-2.3% | 10.84+77.4% | 11.31+95.0% | 12.32+63.4% | 13.71+70.3% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 26.81-5.6% | 27.73-6.2% | 28.67-5.8% | 27.33-13.9% | 28.39+12.4% | 29.56+15.2% | 30.45+14.4% | 31.76+9.3% |
| Total Liabilities | 460.61+15.4% | 467.77+25.6% | 433.77+19.6% | 456.89+32.5% | 398.99+25.6% | 372.37+31.5% | 362.58+60.2% | 344.85+43.6% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 563.27-25.9% | 607.06-23.3% | 662.00-18.3% | 715.50-14.9% | 759.94+13.8% | 791.75+12.4% | 810.76+6.4% | 840.90+5.6% |
| Total Shareholders Equity | 563.27-25.9% | 607.06-23.3% | 662.00-18.3% | 715.50-14.9% | 759.94+13.8% | 791.75+12.4% | 810.76+6.4% | 840.90+5.6% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 563.27-25.9% | 607.06-23.3% | 662.00-18.3% | 715.50-14.9% | 759.94+13.8% | 791.75+12.4% | 810.76+6.4% | 840.90+5.6% |
| Total Liabilities & Stockholders Equity | 1,023.87-11.7% | 1,074.83-7.7% | 1,095.77-6.6% | 1,172.39-1.1% | 1,158.94+17.6% | 1,164.12+17.9% | 1,173.34+18.7% | 1,185.75+14.4% |
| Book Value Per Share per share | 5.01-27.1% | 5.41-24.9% | 5.96-20.3% | 6.47-17.1% | 6.87+1.3% | 7.20+0.3% | 7.48-4.5% | 7.80-4.8% |
| Tangible Book Value Per Share per share | 4.25-33.3% | 4.64-30.6% | 5.28-24.1% | 5.78-20.6% | 6.37+1.8% | 6.69-0.6% | 6.96-9.6% | 7.28-9.6% |
| Full-Time Employees people | - | - | - | 1,784-4.5% | - | - | - | 1,869-14.1% |
| Price to Book Ratio ratio | 5.20 | 3.19 | 2.91 | 2.57 | 4.70 | 4.68 | 4.63 | 3.86 |
| Return on Assets % | -18.23 | -16.86 | -15.75 | -14.93 | -19.29 | -19.78 | -23.32 | -23.13 |
| Return on Equity % | -30.07 | -26.98 | -24.26 | -22.62 | -28.97 | -28.45 | -32.05 | -31.40 |
| Return on Invested Capital % | -8.08 | -8.23 | -7.59 | -6.95 | -4.67 | -5.09 | -5.89 | -9.52 |
| Quick Ratio ratio | 1.84 | 1.92 | 2.19 | 2.27 | 2.68 | 2.93 | 3.09 | 3.38 |
| Current Ratio ratio | 2.04 | 2.13 | 2.40 | 2.45 | 2.87 | 3.12 | 3.26 | 3.51 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -46.24 | -50.88 | -51.17 | -50.63 | -35.99 | -40.95 | -48.44 | -81.68 |
| Depreciation | 5.83+0.9% | 5.85-12.4% | 5.77-2.5% | 5.53+3.4% | 5.78+19.7% | 6.68+33.3% | 5.92+16.5% | 5.35+17.8% |
| Other Funds (Non Cash) | 6.34+291.4% | -0.88-106.6% | -4.80-130.5% | 25.05-36.9% | 1.62-34.4% | 13.33-59.2% | 15.75+6.7% | 39.71+967.5% |
| Funds from Operations | -35.66 | -47.27 | -50.20 | -23.39 | -28.59 | -20.94 | -26.76 | -36.63 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -22.56 | -18.46 | 35.97 | 5.64 | -11.77-256.1% | -10.45-2850.0% | -34.94 | -19.14-126.5% |
| Cash from Operating Activities | -58.22 | -65.73 | -14.22 | -17.75 | -40.36 | -31.38 | -61.70 | -55.77 |
| Capital Expenditures | -12.93 | -1.44 | -22.36 | -1.31 | -4.09 | -4.19 | -3.87 | -17.75 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.23+475.0% | 0.04-20.0% | 0.00 | 0.00 | 0.04 | 0.05+66.7% | 0.00 | -0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00-100.0% | 0.00-100.0% | -9.80 | -0.16 | 2.02 | 330.00+1924.5% | -330.00-2256.9% |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | -10.03 | 0.00 | 0.00 | 0.00 | -330.00-1100000000000000000.0% |
| Sale Or Maturity of Investments | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.22 | -0.16 | 2.02 | 330.00+1924.5% | -3E-14-100.0% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Cash from Investing Activities | -12.71 | -1.40 | -22.35-106.9% | -11.11 | -4.21 | -2.13 | 326.13+9812.8% | -347.75-2504.9% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 2.76+39.4% | 0.95-88.8% | 0.84-60.9% | 0.26-99.9% | 1.98+54.7% | 8.46+21050.0% | 2.15 | 217.95+46272.3% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 2.76+39.4% | 0.95-88.8% | 0.84-60.9% | 0.26-99.9% | 1.98+54.7% | 8.46+21050.0% | 2.15 | 217.95+46272.3% |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | -0.00-100.0% | 0.00 | -0.00 | -0.85 | 216.07 |
| Issuance or Reduction of Debt, Net | 11.56-57.4% | 20.00+2976.9% | 7.03-82.8% | -0.63-103.2% | 27.13-33.7% | 0.65-97.1% | 40.99-15.0% | 19.87 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | -8.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | -8.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 14.31-50.8% | 20.94+129.9% | 7.87-81.8% | -8.81-103.7% | 29.11-31.0% | 9.11-59.2% | 43.14-10.6% | 237.81+60876.9% |
| Exchange Rate Effect | -1.37-821.1% | 2.33+2018.2% | 0.37+1750.0% | 0.17 | 0.19-64.8% | 0.11 | 0.02 | -0.71-197.3% |
| Net Change in Cash | -57.99 | -43.86 | -28.34-109.2% | -37.50 | -15.28 | -24.30 | 307.60 | -166.42-24938.8% |
| Free Cash Flow | -59.17 | -67.04 | -15.42 | -18.43 | -43.37 | -34.28 | -63.23 | -58.37 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| AUGTYRO | 1.09 | 5.54 | +409.0% | 1.2% |
| Nuzyra | 43.20 | 60.84 | +40.8% | 13.3% |
| Optune | 40.48 | 48.33 | +19.4% | 10.6% |
| Product and Service, Other | - | 0.72 | - | 0.2% |
| Qinlock | 28.83 | 35.61 | +23.5% | 7.8% |
| Vyvgart/Vyvgart Hytrulo | 93.64 | 94.20 | +0.6% | 20.6% |
| XACDURO | 3.31 | 22.91 | +593.3% | 5.0% |
| Zejula | 187.08 | 189.04 | +1.0% | 41.3% |
| Total | 397.61 | 457.18 | +15.0% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| China | 397.61 | 457.18 | +15.0% | 100.0% |
| Total | 397.61 | 457.18 | +15.0% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 7.72% | 8.1M | 104.8M | 1.03M |
| 2026-10-15 | 8.44% | 8.8M | 104.8M | 929.04K |
| 2026-09-30 | 6.82% | 7.1M | 104.8M | 940.96K |
| 2026-09-15 | 7.78% | 8.2M | 104.8M | 979.64K |
| 2026-08-31 | 7.65% | 8.0M | 104.8M | 1.01M |
| 2026-08-14 | 7.12% | 7.5M | 104.8M | 962.43K |
| 2026-07-31 | 6.22% | 6.5M | 105.1M | 857.87K |
| 2026-07-15 | 6.04% | 6.4M | 105.2M | 908.91K |
| 2026-06-30 | 7.76% | 8.2M | 105.1M | 894.34K |
| 2026-06-15 | 6.92% | 7.3M | 104.8M | 859.93K |
| 2026-05-29 | 5.90% | 6.5M | 110.7M | 788.12K |
| 2026-05-15 | 4.69% | 5.2M | 110.7M | 743.21K |
| 2026-04-30 | 4.02% | 4.5M | 110.7M | 755.24K |
| 2026-04-15 | 4.96% | 5.5M | 110.8M | 718.69K |
| 2026-03-31 | 4.82% | 5.3M | 110.8M | 740.69K |
| 2026-03-13 | 4.44% | 4.9M | 110.2M | 755.53K |
| 2026-02-27 | 3.45% | 3.8M | 110.2M | 761.84K |
| 2026-02-13 | 3.06% | 3.4M | 110.2M | 834.79K |
| 2026-01-30 | 3.27% | 3.6M | 109.7M | 861.03K |
| 2026-01-15 | 3.56% | 3.9M | 108.9M | 907.34K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 12.50 | 11.40 | 16.00 | 0.00 | 7.087 | 0.00 | 0.00 | 0.926 | -0.153 | 0.005 |
| call | 15.00 | 8.90 | 13.50 | 0.00 | 5.758 | 0.00 | 0.00 | 0.907 | -0.146 | 0.006 |
| call | 17.50 | 6.40 | 11.00 | 0.00 | 4.658 | 0.00 | 0.00 | 0.865 | -0.165 | 0.008 |
| call | 20.00 | 4.00 | 8.50 | 0.00 | 3.699 | 0.00 | 0.00 | 0.826 | -0.149 | 0.010 |
| call | 22.50 | 1.80 | 6.50 | 6.00 | 3.207 | 29.00 | 0.00 | 0.706 | -0.325 | 0.013 |
| call | 25.00 | 0.40 | 5.00 | 2.45 | 3.009 | 5.00 | 0.00 | 0.623 | -0.273 | 0.014 |
| call | 30.00 | 0.00 | 3.00 | 0.75 | 1.958 | 16.00 | 0.00 | 0.364 | -0.180 | 0.014 |
| call | 35.00 | 0.00 | 5.00 | 0.20 | 2.730 | 11.00 | 0.00 | 0.296 | -0.230 | 0.013 |
| put | 12.50 | 0.00 | 5.00 | 0.00 | 4.473 | 0.00 | 0.00 | -0.074 | -0.152 | 0.005 |
| put | 15.00 | 0.00 | 3.00 | 0.05 | 3.562 | 1.00 | 0.00 | -0.093 | -0.144 | 0.006 |
| put | 17.50 | 0.00 | 5.00 | 0.40 | 3.101 | 2.00 | 0.00 | -0.135 | -0.163 | 0.008 |
| put | 20.00 | 0.00 | 1.00 | 0.79 | 4.017 | 2,700 | 0.00 | -0.224 | -0.279 | 0.012 |
| put | 22.50 | 0.10 | 4.90 | 0.40 | 3.862 | 59.00 | 4.00 | -0.294 | -0.323 | 0.013 |
| put | 25.00 | 0.00 | 3.80 | 2.51 | 2.914 | 24.00 | 0.00 | -0.377 | -0.271 | 0.014 |
| put | 30.00 | 1.50 | 6.30 | 5.50 | 2.345 | 3.00 | 0.00 | -0.636 | -0.177 | 0.014 |
| put | 35.00 | 6.50 | 11.20 | 10.00 | 3.219 | 2.00 | 0.00 | -0.704 | -0.226 | 0.013 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-09 | D | Notice of sales of securities on Form D (Regulation D) | SEC | |
| 2026-11-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-10-23 | 8-K | Current report | 2026-10-22 | SEC |
| 2026-10-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-19 | SEC |
| 2026-08-20 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-08-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-07-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-01 | SEC |
| 2026-07-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-01 | SEC |
| 2026-07-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-29 | SEC |
| 2026-06-30 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-22 | SEC |
| 2026-06-22 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 235.15K | 3 |
| 2026-07 | 33.07K | 1 | 0 | 0 |
| 2026-06 | 0 | 0 | 797.29K | 5 |
| 2026-05 | 0 | 0 | 4.06M | 5 |
| 2026-04 | 0 | 0 | 917.73K | 10 |
| 2026-03 | 32.73K | 1 | 4.48M | 11 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 336.32K | 2 |
| 2025-11 | 0 | 0 | 289.85K | 2 |
Institutional holders
| Manager | % owned |
|---|---|
| RTW INVESTMENTS, LP | 5.82% |
| TCG Crossover Management, LLC | 5.44% |
| RA CAPITAL MANAGEMENT, L.P. | 5.09% |
| ADAR1 Capital Management, LLC | 2.98% |
| GOLDMAN SACHS GROUP INC | 2.05% |
| Woodline Partners LP | 1.95% |
| Frazier Life Sciences Management, L.P. | 1.68% |
| BAMCO INC /NY/ | 1.44% |
| TWO SIGMA INVESTMENTS, LP | 1.15% |
| CITADEL ADVISORS LLC | 1.14% |
Funds
| Fund | % owned |
|---|---|
| Baron Emerging Markets Fund | 1.21% |
| Strategic Advisers Fidelity Emerging Markets Fund | 0.66% |
| iShares Biotechnology ETF | 0.56% |
| Fidelity Growth Company Fund | 0.29% |
| abrdn World Healthcare Fund | 0.28% |
| Strategic Advisers Emerging Markets Fund | 0.18% |
| Fidelity Pacific Basin Fund | 0.14% |
| Tema Oncology ETF | 0.14% |
| ALPS Medical Breakthroughs ETF | 0.12% |
| Fidelity Growth Company K6 Fund | 0.12% |
OakChart. ZLAB. Cached 15 minutes. Terms